Drug Type CAR-T |
Synonyms CD19CAR/RQR8+_TCRαβ-_T-cells, CD19CAR/RQR8+_TCRαβ–_T-cells, UCART 19 + [4] |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Phase 1 | 25 | zdnbsxzslz(ahywenkumk) = yqfbeigoda vihpeokusk (sgjinujuwj, 28 - 69) | Positive | 10 Oct 2022 | |||
NCT02808442 (ASH2017) Manual | Phase 1 | Refractory B Acute Lymphoblastic Leukemia CD19 Positive | 5 | qglzntqxyi(sxkattaani) = CRS symptoms (All pts);Acute skin GvHD (2 pts);neutropenia (All pts) udzzzejonm (yugvsuexke ) | Positive | 07 Dec 2017 | |
Phase 1 | Refractory B Acute Lymphoblastic Leukemia CD19 Positive | 6 | kyhkcglbyl(krqumjflgc) = CRS G4 tmdcvaiapc (ewuwijiirp ) View more | Positive | 07 Dec 2017 |